MEI Pharma (MEIP)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.95 mm	6.95 mm	6.95 mm	6.95 mm	6.95 mm	6.95 mm
Cash burn (monthly)	(no burn)	(no burn)	2.78 mm	4.09 mm	3.82 mm	3.62 mm
Cash used (since last report)	n/a	n/a	11.89 mm	17.47 mm	16.30 mm	15.45 mm
Cash remaining	n/a	n/a	-4.94 mm	-10.52 mm	-9.35 mm	-8.50 mm
Runway (months of cash)	n/a	n/a	-1.8	-2.6	-2.4	-2.3

Beta Read what these cash burn values mean

Financial data from MEI Pharma earnings reports.

Institutional ownership, Q3 2024

MEIP institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	35	37	-5.4%
Opened positions	6	3	+100.0%
Closed positions	8	2	+300.0%
Increased positions	6	7	-14.3%
Reduced positions	9	12	-25.0%

13F shares	Current	Prev Q	Change
Total value	7.47 bn	7.56 bn	-1.2%
Total shares	24.54 mm	24.53 mm	+0.0%
Total puts	0.00	600.00	EXIT
Total calls	0.00	19.20 k	EXIT
Total put/call ratio	–	0.0	–

Largest owners	Shares	Value	Change
Growth Equity Opportunities V	9.96 mm	$17.93 mm	0.0%
Biotechnology Value Fund L P	5.59 mm	$14.76 mm	0.0%
Vivo Opportunity	3.30 mm	$8.71 mm	0.0%
Helsinn Investment Fund	2.62 mm	$6.49 mm	0.0%
Anson Funds Management	1.09 mm	$3.12 bn	0.0%
Cable Car Capital	611.44 k	$1.74 bn	-0.0%
Vanguard	385.73 k	$1.10 bn	-1.0%
Tang Capital Partners	326.08 k	$1.51 mm	0.0%
Renaissance Technologies	137.65 k	$392.29 mm	-5.3%
Acadian Asset Management	132.36 k	$377.00 k	-11.8%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-74.67 k	EXIT
BlackRock	67.26 k	+67.26 k	NEW
Pensionmark Financial	25.00 k	+25.00 k	NEW
Corsair Capital Management	24.37 k	+24.37 k	NEW
Acadian Asset Management	132.36 k	-17.79 k	-11.8%
Citadel Advisors	0.00	-15.89 k	EXIT
Geode Capital Management	59.30 k	+8.01 k	+15.6%
Renaissance Technologies	137.65 k	-7.65 k	-5.3%
FNY Investment Advisers	7.01 k	+7.01 k	NEW
Dimensional Fund Advisors	23.43 k	+6.86 k	+41.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MEIP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
17 May 24	Steven D Wood	Common Stock	Grant	Acquire A	No	No	3.1701	3,100	9.83 k	4,359
16 May 24	James P Flynn	Common Stock	Grant	Acquire A	No	No	3.1621	7,900	24.98 k	7,900
18 Dec 23	James P Flynn	Stock Option Common Stock	Grant	Acquire A	No	No	6.33	10,000	63.30 k	10,000
18 Dec 23	James P Flynn	Stock Options Common Stock	Grant	Acquire A	No	No	6.33	6,700	42.41 k	6,700
18 Dec 23	Steven D Wood	Stock Option Common Stock	Grant	Acquire A	No	No	6.19	10,000	61.90 k	10,000
18 Dec 23	Steven D Wood	Stock Option Common Stock	Grant	Acquire A	No	No	6.19	6,700	41.47 k	6,700

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining

22 Nov 24

Darwin Financial's Joshua Robinson talks to Benzinga about the firm's latest commodities deal, and more M&A news from this past week.

Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul

17 Nov 24

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has the latest M&A updates.

MEI Pharma Q1 EPS $(1.20) Down From $8.46 YoY

12 Nov 24

MEI Pharma (NASDAQ:MEIP) reported quarterly losses of $(1.20) per share. This is a 114.18 percent decrease over earnings of $8.46 per share from the same period last year.

Press releases

From Benzinga Pro

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

12 Nov 24

Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024,